



EDITION

16th MILAN CONGRESS ON
**Innovative
Anticancer
Therapy**

PRELIMINARY PROGRAM



RESIDENTIAL CONGRESS 2026

January 29th from 05.00 p.m. to 06.00 p.m.

January 30th from 09.30 a.m. to 05.45 p.m.

Aula Magna Gianni Bonadonna
Fondazione IRCCS Istituto Nazionale dei Tumori
Via G. Venezian, 1 - MILAN

Sistema Socio Sanitario

 **Fondazione IRCCS**
Istituto Nazionale dei Tumori

 **Regione
Lombardia**



PATRONAGE REQUESTED

- **AIOM**
Associazione Italiana Oncologia Medica

- **Fondazione IRCCS**
Istituto Nazionale dei Tumori

- **OMCeO Milano**
Ordine Provinciale dei Medici Chirurghi
e degli Odontoiatri



RATIONALE

In the last decade, adoptive cell therapies and in particular CAR T cells have dramatically changed the therapeutic landscape of hematological malignancies, providing hope where traditional treatments had failed. Their progressive expansion into the field of solid tumors confirms the extraordinary potential of cellular immunotherapy, yet also highlights the many challenges that still need to be addressed. Resistance to therapy, tumor escape mechanisms, the hostile microenvironment that limits T cell activity, and the persistence of treatment-related toxicities all represent major obstacles that must be overcome in order to fully realize the promise of these revolutionary strategies.

The 16th "Milan Congress on Anticancer Innovative Therapy" Conference has been designed to create a space where leading international and national experts can come together to share the most recent discoveries and discuss how to translate them into effective clinical solutions. The first part of the program will focus on the biological and technological foundations of therapy resistance and on the development of new strategies to overcome it. Topics will range from the dissection of resistance mechanisms in CAR T cell therapy to the design of innovative non-viral CAR platforms and the optimization of novel constructs targeting solid tumors. Particular attention will be given to the reprogramming of T cells in order to boost their persistence, functionality, and ability to bypass resistance to immune checkpoint inhibitors.

The second part of the meeting will shift the focus towards clinical translation, offering a comprehensive overview of how these insights are being integrated into therapeutic strategies for different tumor types. The program will explore T cell metabolism as a novel therapeutic target, present innovative treatment approaches for hormone receptor-positive breast cancer and HER2-positive breast cancer stem cells resistant to targeted therapy, and address the modulation of the gut microbiota-immunity axis as a powerful tool in plasma cell dyscrasias. Finally, this year's edition includes a report on recent advances in neoadjuvant and adjuvant strategies for cutaneous and uveal melanoma, which will illustrate how innovative immunotherapy concepts are already making their way into clinical practice. By alternating state-of-the-art lectures with interactive discussions, the meeting will provide participants with not only an up-to-date picture of where the field currently stands, but also a forward-looking vision of where it is heading. The ultimate goal is to stimulate dialogue between basic science and clinical research, fostering collaborations that can accelerate the journey from laboratory discoveries to therapeutic applications.

We genuinely believe that this event presents an amazing opportunity for you to expand your knowledge, network with industry leaders, and contribute to the advancement in the biology and the treatment of cancer patients.



SCIENTIFIC HEADS

FILIPPO DE BRAUD (Milan, Italy)

MICHELE DEL VECCHIO (Milan, Italy)

MASSIMO DI NICOLA (Milan, Italy)

SCIENTIFIC BOARD

GIOVANNI APOLONE (Milan, Italy)

FILIPPO DE BRAUD (Milan, Italy)

MICHELE DEL VECCHIO (Milan, Italy)

MASSIMO DI NICOLA (Milan, Italy)

GIANPIETRO DOTTI (Chapel Hill, USA)

LUCA GATTINONI (Regensburg, Germany)



FACULTY

- **ANA ARANCE**
Hospital Clinic of Barcelona, Spain
- **MATTEO BELLONE**
San Raffaele Hospital, Milan, Italy
- **FILIPPO DE BRAUD**
Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
- **MICHELE DEL VECCHIO**
Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
- **MASSIMO DI NICOLA**
Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
- **GIANPIETRO DOTTI**
University of North Carolina, Lineberger Comprehensive Cancer Center, Chapel Hill, USA
- **WOLF FRIDMAN**
University of Paris; Cordeliers Research Centre, Paris, France
- **LUCA GATTINONI**
Head of Division of Functional Immune Cell Modulation
Leibniz Institute for Immunotherapy, Regensburg, Germany
- **MICHELE MAIO**
University of Siena, Siena, Italy
- **MASSIMO MASSAIA**
University of Turin, Turin, Italy
- **SERENELLA PUPA**
Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
- **FRANCESCA PUTTI**
Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
- **MARCO RUELLA**
University of Pennsylvania, Pennsylvania, USA
- **SARA TETTAMANTI**
IRCCS San Gerardo Hospital of Monza, Milan, Italy
- **Alberto ZAMBELLI**
Giovanni XXIII Bergamo Hospital, Bergamo, Italy



29th JANUARY 2026 · SCIENTIFIC PROGRAM

16.30-17.00 Registration

17.00-17.15 Introduction to the Lecture
Massimo DI NICOLA (Milan, Italy)

17.15-18.00 New frontiers in anticancer immunotherapy
Wolf FRIDMAN (Paris, France)

18.00 Welcome Cocktail

30th JANUARY 2026 · SCIENTIFIC PROGRAM

09.30-09.40 Institutional greetings
Gustavo Galmozzi, President, Fondazione IRCCS INT
Maria Teresa Montella, General Manager, Fondazione IRCCS INT
Paolo Corradini, Scientific Director, Fondazione IRCCS INT

I SESSION: New insights on CART and immunotherapy

Chairmen: **Filippo DE BRAUD**, **Luca GATTINONI**

09.40-10.10 Mechanism of resistance to CART - **Marco RUELLA**
10.10-10.25 Discussion
10.25-10.55 Non-viral CARCIK for the treatment of hematological diseases - **Sarah TETTAMANTI**
10.55-11.10 Discussion
11.10-11.40 Design, development and optimization of novel anti-Globo H CAR T cells in solid tumors - **Francesca PUTTI**
11.40-11.55 Discussion
11.55-12.25 Reprogramming T cells to overcome the resistance to checkpoint inhibitors - **Michele MAIO**
12.25-12.40 Discussion
12.40-14.40 Lunch

II SESSION: Clinical translation

Chairmen: **Giampiero DOTTI**, **Massimo MASSAIA**

14.40-15.10 Cancer and T cell metabolism: potential target of anticancer therapeutics - **Filippo DE BRAUD**
15.10-15.25 Discussion
15.25-15.55 Hormone-positive breast cancer: novel innovative approaches for recurrent patients - **Alberto ZAMBELLI**
15.55-16.10 Discussion
16.10-16.40 Fatty Acid uptake as novel actionable target of HER2-positive breast cancer stem cells resistant to targeted therapy - **Serenella PUPA**
16.40-16.55 Discussion
16.55-17.25 Exploiting the gut microbiota-immunity axis for cancer immunotherapy in plasma cell dyscrasias - **Matteo BELLONE**
17.25-17.40 Discussion
17.40-18.00 Neoadjuvant therapy in cutaneous melanoma and immunotherapy of metastatic uveal melanoma: a step forward - **Ana ARANCE**
18.00-18.10 Discussion
18.10-18.20 Conclusions - **Michele DEL VECCHIO**
18.20-18.40 Delivery and compilation CME questionnaire

GENERAL INFORMATIONS

Date

Thursday, 29th January 2026
from 05.00 p.m. to 06.00 p.m.

Friday, 30th January 2026
from 09.30 a.m. to 05.45 p.m.

Congress Venue

Aula Magna Gianni Bonadonna
Fondazione IRCCS Istituto Nazionale dei Tumori
Via G. Venezian, 1 - MILAN

Official language

English

CME Provider Nr. 265 Organizing Secretariat



Nadirex International Srl
Via Riviera 39 · 27100 Pavia

Project Manager: Dr.ssa Gloria Molla
Mob 347 8589333 - gloria.molla@nadirex.com
www.nadirex.org

Registration

The registration is free and includes:

- Participation in the conference work
- Congress Kit
- Certificate of Attendance
- CME credits Certificate
- Welcome coffee and lunch as scheduled
- Post-event educational material
- Hostess assistance

Registration instructions

Registration is free and can be made on-line at www.nadirex.org
The Congress is not by direct invitation of the Sponsor.

CME INFORMATIONS

Id ECM: 265-466537

CME credits: 9

- **Participants:** 100
- **Learning hours:** 8
- **Educational goal:** Nr. 3 - Clinical documentation. Diagnostic and rehabilitative clinical-assistance paths, assistance profiles - treatment profiles

- **Addresses of the Congress**

The Congress is addressed to the following figures:

- Medico Chirurgo
(Discipline: tutte le discipline)
- Psicologo (Psicoterapia, Psicologia)
- Biologo - Biotecnologo (Biologo - Biotecnologo)
- Tecnico Sanitario Laboratorio Biomedico (Tecnico Sanitario Laboratorio Biomedico)
- Tecnico Sanitario di Radiologia Medica (Tecnico Sanitario di Radiologia Medica)
- Farmacisa (Farmacista Pubblica del SSN, Farmacista Territoriale)
- Chimico (Chimica Analitica)
- Infermiere

In order to obtain CME credits, participants must:

- Participate in 90% of training activities
- Complete the ECM questionnaire correctly (the attribution of credits is subject to exceeding 75% correct answers)
- Fill in the RES event perceived quality sheet
- Fill in the training needs survey form
- Sign the attendance register at the beginning and end of the work
- Having completed the recruitment declaration by Sponsor (to be delivered at the beginning of the day)

WITH THE UNRESTRICTED
EDUCATIONAL GRANTS OF:



IMMUNOCORE

REGENERON



LABORATOIRES

Pierre Fabre

Innovative Oncology

